Article

Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction.

Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, 3 East Qing Chun Road, Hangzhou 310016, China.
European Journal of Cardio-Thoracic Surgery (impact factor: 2.55). 04/2007; 31(3):438-43. DOI:10.1016/j.ejcts.2006.11.057 pp.438-43
Source: PubMed

ABSTRACT This study was designed to determine the optimal time point for bone marrow mesenchymal stem cell (MSC) transplantation after myocardial infarction (MI).
MSCs from donor rats were labeled with DAPI before transplantation. The animals underwent MI by ligation of left anterior descending coronary artery, and received intramyocardial injection of MSCs at 1h, 1 week and 2 weeks after MI, respectively. Sham-operated and MI control groups received equal volume phosphate buffered saline. Cardiac function, histological analysis and immunoblot for troponin T were performed 4 weeks after cell transplantation.
MSC transplantation attenuated left ventricular chamber dilation, reduced infarct size, and improved cardiac function in rats after MI. The greatest benefit was achieved in rats that received cells 1 week after MI, engrafted MSC survival, angiogenesis and functional cardiomyocytes in the injured hearts were more abundant in these rats than that in other transplantation groups.
The optimal functional benefit of MSC transplantation was observed in 1-week transplantation group. At this time point scar formation has not occurred and the inflammation is reduced, which should facilitate integration of transplanted cells and functional recovery.

0 0
 · 
0 Bookmarks
 · 
21 Views
  • Source
    Article: Human mesenchymal stem cells: From immunophenotyping by flow cytometry to clinical applications.
    Arthur A Nery, Isis C Nascimento, Talita Glaser, Vinicius Bassaneze, José E Krieger, Henning Ulrich
    [show abstract] [hide abstract]
    ABSTRACT: Modern medicine will unequivocally include regenerative medicine as a major breakthrough in the re-establishment of damaged or lost tissues due to degenerative diseases or injury. In this scenario, millions of patients worldwide can have their quality of life improved by stem cell implantation coupled with endogenous secretion or administration of survival and differentiation promoting factors. Large efforts, relying mostly on flow cytometry and imaging techniques, have been put into cell isolation, immunophenotyping, and studies of differentiation properties of stem cells of diverse origins. Mesenchymal stem cells (MSCs) are particularly relevant for therapy due to their simplicity of isolation. A minimal phenotypic pattern for the identification of MSCs cells requires them to be immunopositive for CD73, CD90, and CD105 expression, while being negative for CD34, CD45, and HLA-DR and other surface markers. MSCs identified by their cell surface marker expression pattern can be readily purified from patient's bone marrow and adipose tissues. Following expansion and/or predifferentiation into a desired tissue type, stem cells can be reimplanted for tissue repair in the same patient, virtually eliminating rejection problems. Transplantation of MSCs is subject of almost 200 clinical trials to cure and treat a very broad range of conditions, including bone, heart, and neurodegenerative diseases. Immediate or medium term improvements of clinical symptoms have been reported as results of many clinical studies. © 2012 International Society for Advancement of Cytometry.
    Cytometry Part A 10/2012; · 3.73 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

1-week transplantation group
 
anterior descending coronary artery
 
bone marrow mesenchymal
 
cardiac function
 
cell transplantation
 
engrafted MSC survival
 
functional cardiomyocytes
 
functional recovery
 
histological analysis
 
MI control groups
 
MSC transplantation
 
MSC transplantation attenuated
 
myocardial infarction
 
optimal functional benefit
 
optimal time point
 
received cells 1 week
 
time point
 
transplantation groups
 
troponin T
 
ventricular chamber dilation
 

Xinyang Hu